Exosomes Clinical Trials 2024: FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight

(Albany, USA) DelveInsight's 'Exosomes Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline exosomes-based therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the exosomes-based therapies pipeline domain.

Request for sample report @ https://www.delveinsight.com/report-store/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Exosomes-based Therapies Pipeline Report
• DelveInsight's exosomes pipeline report depicts a robust space with 70+ active players working to develop 80+ pipeline therapies for various indications.
• Key exosomes-based therapies companies such as Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics, Exostemtech, Brexogen, OmniSpirant, ShiftBio Inc., and others are evaluating new exosomes-based therapies to improve the treatment landscape.
• Promising exosomes-based therapies in the pipeline in various stages of development include CAP-1002, Progenza, AGLE 102, ExoCoVac, COYA 201, EV-101, StemXO Endosome Therapy, BRE AD01, ILB 202, Zofin, exoSTING, ExoFlo, CARTISOME, BRE MI01, OS006, SBI-407, and others.
• In July 2024, Aruna Bio announced the issuance of a US Patent for the composition of matter for neural exosomes used to deliver therapeutics to the brain. The company is on a rack to initiate Phase Ib/IIa clinical trial of AB126 in acute ischemic stroke in the second half of 2024.
• In July 2024, ILIAS Biologics announced that it had received the final clinical study report (CSR) for ILB-202, a Phase I clinical trial completed in Australia in November last year.
• In April 2024, Biological Dynamics joined the growing list of customers adopting the ExoVerita Pro instrument, a cost-efficient, automated exosomal enrichment platform.
• In April 2024, EXO Biologics secures up to EUR 16 million in Series A funding for exosome therapeutic development and clinical supply.
• In April 2024, ExoXpert entered a strategic partnership with Neucore Bio to leverage ExoXpert's platform for the evaluation of advanced exosome loading.
• In April 2024, INOVIQ and Promega signed a global supply and distribution agreement for EXO-NET. Last year's company entered into a Co-Marketing agreement.
• In March 2024, VivaZome Therapeutics and La Trobe University collaborated to explore the therapeutic potential of extracellular vesicles in models of stroke in the laboratory of Professor Chris Sobey.
• In January 2024, Aegle Therapeutics announced positive 12-week data for the first patient enrolled in Phase I/IIa clinical trial of AGLE-102 for the treatment of severe second-degree burns.

Request a sample and discover the recent advances in exosomes-based therapies @ Exosomes Pipeline Outlook - https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The exosomes-based therapies pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage exosomes-based therapies, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the exosomes-based therapies pipeline landscape.

Exosomes Overview
Exosomes are small extracellular vesicles, typically ranging from 30 to 150 nanometres in diameter that are secreted by various cell types. They play a crucial role in intercellular communication by facilitating the transfer of proteins, lipids, and RNA between cells. This process can influence various physiological and pathological conditions, including immune responses, cancer progression, and neurodegenerative diseases. By carrying bioactive molecules, exosomes can modulate the behaviour of recipient cells, contributing to processes such as tissue repair, immune regulation, and the spread of cancer cells. Their ability to transport molecular cargo makes them a subject of extensive research, particularly in the context of disease mechanisms and therapeutic applications.
In recent years, exosomes have garnered significant interest in the field of biomedicine as potential biomarkers for disease diagnosis and as vehicles for targeted drug delivery. Researchers are exploring their use in therapeutic strategies, such as the delivery of RNA-based therapies and proteins, due to their natural ability to evade the immune system and penetrate cellular membranes. Additionally, exosomes derived from stem cells or engineered for specific therapeutic purposes hold promise for regenerative medicine, offering a novel approach to enhance tissue regeneration and repair. The ongoing investigation into the biology of exosomes continues to reveal their multifaceted roles in health and disease, paving the way for innovative applications in diagnostics and therapeutics.

Learn more about the emerging Exosomes-based therapies @ Exosomes-based Therapies Clinical Trials - https://www.delveinsight.com/report-store/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Exosomes-based Therapies Therapeutics Assessment
The exosome-based therapies pipeline report proffers an integral view of the emerging exosome-based therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Exosomes-based Therapies Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Therapeutics Assessment By Mechanism of Action: Cell replacements, Inflammation mediator modulators, Collagen type VII replacements, Immunosuppressants, NF-kappa B inhibitor
• Key Exosomes-based Therapies Companies: Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics, Exostemtech, Brexogen, OmniSpirant, ShiftBio Inc., and others.
• Key Exosomes-based Therapies in Pipeline: CAP-1002, Progenza, AGLE 102, ExoCoVac, COYA 201, EV-101, StemXO Endosome Therapy, BRE AD01, ILB 202, Zofin, exoSTING, ExoFlo, CARTISOME, BRE MI01, OS006, SBI-407, and others.

Dive deep into rich insights for exosomes-based therapies assessment, visit @ Exosomes-based Therapies Therapeutics Assessment - https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Exosomes-based Therapies Pipeline Report Introduction
2. Exosomes-based Therapies Pipeline Report Executive Summary
3. Exosomes-based Therapies Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Exosomes-based Therapies Pipeline Therapeutics
6. Exosomes-based Therapies Pipeline: Late Stage Products (Pre-registration)
7. Exosomes-based Therapies Pipeline: Late Stage Products (Phase III)
8. Exosomes-based Therapies Pipeline: Mid Stage Products (Phase II)
9 Exosomes-based Therapies Pipeline: Early Stage Products (Phase I)
10. Exosomes-based Therapies Pipeline Therapeutics Assessment
11. Inactive Products in the Exosomes-based Therapies Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the Exosomes-based Therapies Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the exosomes-based therapies pipeline therapeutics, reach out @ Exosomes-based Therapies Pipeline Landscape - https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Acne Vulgaris Market: https://www.delveinsight.com/report-store/acne-vulgaris-av-market
• Diffuse Large B-cell Lymphoma Market: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market
• Hepatic Encephalopathy Market: https://www.delveinsight.com/report-store/hepatic-encephalopathy-market
• Osteochondromas Market: https://www.delveinsight.com/report-store/osteochondromas-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Nontuberculous Mycobacteria Infection Market: https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market
• Sjogren's Syndrome Market: https://www.delveinsight.com/report-store/sjogrens-syndrome-market-size
• Walking Impairment In Multiple Sclerosis Market: https://www.delveinsight.com/report-store/walking-impairment-in-multiple-sclerosis-market
• Acute Lung Injury Market: https://www.delveinsight.com/report-store/acute-lung-injury-market
• Central Retinal Venous Occulsion Market: https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
• Chronic Cutaneous Ulcer Market: https://www.delveinsight.com/report-store/chronic-cutaneous-ulcer-market
• Ambulatory Arrhythmia Monitoring Devices Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Giant Papillary Conjunctivitis Market: https://www.delveinsight.com/report-store/giant-papillary-conjunctivitis-market
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Spasticity Market: https://www.delveinsight.com/report-store/spasticity-market
• Chronic Insomnia Market: https://www.delveinsight.com/report-store/insomnia-market
• Chronic Obstructive Pulmonary Disease Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/competitive-benchmarking-services
Case Study: https://www.delveinsight.com/case-study/asset-prioritization

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.